Therapy News and Research

RSS

$ProNAi enrolls first patient in PNT2258 Phase II study for treatment of refractory or relapsed DLBCL$

ProNAi enrolls first patient in PNT2258 Phase II study for treatment of refractory or relapsed DLBCL

ProNAi Therapeutics Inc., a private hematology/oncology company dedicated to developing and commercializing a new class of therapeutics based on its proprietary DNAi platform, today reported that the first patient with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) has enrolled in the "Wolverine" Phase II study and been treated with PNT2258.

8 Jan 2015

Helsinn, Pharmacosmos sign license agreement for commercialization of Monofer in the US

Helsinn Group and Pharmacosmos A/S today jointly announce that they have entered into an agreement for the exclusive US commercialization rights to Monofer, an innovative intravenous iron replacement therapy under development for the treatment of Iron Deficiency Anemia.

8 Jan 2015

Carl Zeiss Meditec to invest in Oraya Therapy for treatment of wet AMD

Carl Zeiss Meditec AG and Oraya Therapeutics, Inc. jointly announced today that the companies have entered into a collaboration agreement under which Carl Zeiss Meditec will provide funding to Oraya over a period of up to two years for the implementation of Oraya’s growth strategy, and in turn receive rights in the company reaching up to a majority stake after two years.

8 Jan 2015

Ferrer partners with Cipher Pharmaceuticals to bring Ozenoxacin to the Canadian market

Ferrer, a privately-held Spanish pharmaceutical company, today announces that it has licensed commercialisation rights for Ozenoxacin one per cent cream in Canada to Cipher Pharmaceuticals Inc.

8 Jan 2015

Combination therapy can reduce recurrence of small, HER2-positive breast tumors

In a phase 2 clinical trial, women with small (stage 1), HER2-positive breast tumors who received a combination of lower-intensity chemotherapy and a targeted drug following surgery were highly unlikely to have the cancer recur within three years of treatment, investigators at Dana-Farber Cancer Institute and other institutions report in a paper published today by the New England Journal of Medicine.

8 Jan 2015

Testosterone therapy suppresses some advanced prostate cancers, find Johns Hopkins scientists

In a surprising paradox, the male hormone testosterone, generally thought to be a feeder of prostate cancer, has been found to suppress some advanced prostate cancers and also may reverse resistance to testosterone-blocking drugs used to treat prostate cancer.

8 Jan 2015

Study: Synthetic triglyceride oil may provide hope for people with Huntington's disease

An early study suggests that a synthetic triglyceride oil called triheptanoin may provide hope for people with Huntington's disease. The study is published in the January 7, 2015, online issue of Neurology, the medical journal of the American Academy of Neurology.

7 Jan 2015

Kyowa Hakko Kirin and Syndax sign agreement to develop entinostat in Japan and Korea

Kyowa Hakko Kirin Co., Ltd., (Headquarters: Chiyoda-ku, Tokyo; president and CEO: Nobuo Hanai, "Kyowa Hakko Kirin") and Syndax Pharmaceuticals, Inc., (Waltham, Mass.; president and CEO: Arlene M. Morris, "Syndax") today jointly announced that the companies have entered into a license agreement for the exclusive rights to develop and commercialize entinostat in Japan and Korea.

7 Jan 2015

EarlySense brings Bedside Monitor and Central Display System to Canadian Market

EarlySense, the market leader in contact-free monitoring solutions today announced an approval to distribute its latest Bedside Monitor and Central Display System in the Canadian Market. EarlySense is bringing to Canada a unique solution that empowers clinicians to provide efficient, safe care based on early indication of high risk situations for falls, pressure ulcers or deterioration such as caused by Opioid therapy.

7 Jan 2015

CET ‘feasible’ in schizophrenia patients with substance misuse

Patients with schizophrenia and comorbid substance abuse diagnoses are able to benefit from cognitive enhancement therapy, preliminary research suggests.

7 Jan 2015

Soligenix's SGX301 receives FDA 'Fast Track' designation for CTCL treatment

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that its SGX301 (synthetic hypericin) development program for the first-line treatment of cutaneous T-cell lymphoma (CTCL) has received "Fast Track" designation from the US Food and Drug Administration.

7 Jan 2015

Study finds unnecessary hysterectomy in 1 out of 5 cases

It is estimated that one in three women in the United States will have had a hysterectomy by the age of 60. Although the numbers of hysterectomies are decreasing, a new study of more than three thousand women in Michigan who underwent hysterectomy for benign indications reveals that alternatives to hysterectomy are being underused and that treatment guidelines are often not followed.

7 Jan 2015

Researchers examine ischemic complications in patients who receive flow-diverting stents

The use of flow-diverting stents to treat intracranial aneurysms appears safe and highly successful. Recently, however, there have been reports of ischemic complications occurring in brain territories supplied by the parent artery in which the stent is placed and in brain regions fed by small arterial branches whose ostia are covered by the stent.

7 Jan 2015

UCLA researchers develop method that defines unique stages of reprogramming skin cells

In a groundbreaking study that provides scientists with a critical new understanding of stem cell development and its role in disease, UCLA researchers at the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research led by Dr. Kathrin Plath, professor of biological chemistry, have established a first-of-its-kind methodology that defines the unique stages by which specialized cells are reprogrammed into stem cells that resemble those found in the embryo.

7 Jan 2015

Gamida Cell granted FDA and EMA orphan drug designation for NiCord

Gamida Cell, a leader in cell therapy technologies and products for transplantation and adaptive immune therapy, announced today that orphan drug designation has been granted by The US Department of Health and Human Services, The FDA Office of Orphan Products Development (OOPD) for the investigational medicinal product NiCord for the treatment of acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), Hodgkin lymphoma and myelodysplastic syndrome (MDS).

6 Jan 2015

Adding radiation treatment to hormone therapy saves older men with prostate cancer

Adding radiation treatment to hormone therapy saves more lives among older men with locally advanced prostate therapy than hormone therapy alone, according to a new study in the Journal of Clinical Oncology this week from Penn Medicine researchers.

6 Jan 2015

Many breast cancer patients undergoing lumpectomy surgery benefit from new intra-operative technology

Many patients undergoing lumpectomy surgery at NYU Langone Medical Center for the removal of an early detected breast tumor - the surgical option of choice for this diagnosis -- are benefitting from new intra-operative technology that detects microscopic amounts of cancer cells on removed tumor tissue not visible during or following surgical intervention.

6 Jan 2015

Johns Hopkins scientists use genome editing technology to alter human stem cells

A powerful “genome editing” technology known as CRISPR has been used by researchers since 2012 to trim, disrupt, replace or add to sequences of an organism’s DNA.

6 Jan 2015

BrainStorm's phase 2a ALS study meets primary endpoint

BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced positive final results from its phase 2a clinical trial of NurOwn™ in amyotrophic lateral sclerosis (ALS) patients, which enrolled 14 subjects at Hadassah Medical Center in Jerusalem.

6 Jan 2015

Oncoceutics, MD Anderson partner to develop novel anti-cancer drug

Oncoceutics Inc. and The University of Texas MD Anderson Cancer Center today announced the initiation of a strategic alliance and research collaboration agreement for the clinical development of ONC201, a novel anti-cancer drug.

5 Jan 2015

Therapy News and Research

ProNAi enrolls first patient in PNT2258 Phase II study for treatment of refractory or relapsed DLBCL

Helsinn, Pharmacosmos sign license agreement for commercialization of Monofer in the US

Carl Zeiss Meditec to invest in Oraya Therapy for treatment of wet AMD

Ferrer partners with Cipher Pharmaceuticals to bring Ozenoxacin to the Canadian market

Combination therapy can reduce recurrence of small, HER2-positive breast tumors

Testosterone therapy suppresses some advanced prostate cancers, find Johns Hopkins scientists

Study: Synthetic triglyceride oil may provide hope for people with Huntington's disease

Kyowa Hakko Kirin and Syndax sign agreement to develop entinostat in Japan and Korea

EarlySense brings Bedside Monitor and Central Display System to Canadian Market

CET ‘feasible’ in schizophrenia patients with substance misuse

Soligenix's SGX301 receives FDA 'Fast Track' designation for CTCL treatment

Study finds unnecessary hysterectomy in 1 out of 5 cases

Researchers examine ischemic complications in patients who receive flow-diverting stents

UCLA researchers develop method that defines unique stages of reprogramming skin cells

Gamida Cell granted FDA and EMA orphan drug designation for NiCord

Adding radiation treatment to hormone therapy saves older men with prostate cancer

Many breast cancer patients undergoing lumpectomy surgery benefit from new intra-operative technology

Johns Hopkins scientists use genome editing technology to alter human stem cells

BrainStorm's phase 2a ALS study meets primary endpoint

Oncoceutics, MD Anderson partner to develop novel anti-cancer drug

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News